Abstract 582P
Background
Leptomeningeal metastases (LM) is one of the most severe complications of NSCLC and always accompanied with poor prognosis. Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with high brain penetration and wide therapeutic window. This study aims to evaluate the efficacy and safety of furmonertinib at 240mg/day in EGFR mutated NSCLC patients with leptomeningeal metastases (LM).
Methods
Patients were diagnosed as LM according to EANO-ESMO criteria. The primary endpoint was overall survival (OS), time to treatment discontinuation (TTD) and clinical response rate were secondary endpoints. Clinical response rate assessed with improvement of neurologic symptoms or signs and changes in the performance status. LM were assessed by investigator according to RANO-LM radiologic criteria.
Results
Between May 2021 and August 2023, 31 patients at Henan Cancer Hospital were enrolled. 26 (83.9%) patients received EGFR-TKI therapy prior to receive furmonertinib, 19 (61.3%) patients received at least 2 lines treatment, 21 (67.7%) patients received other 3rd generation EGFR-TKI therapy. The median age was 58 years (range:36-75), 23 (74.2%) were females. 21 (67.7%) patients with ECOG 3. 23 OS events had occurred at the data cut-off (1 August 2023), Median OS was 8.433 months (95%CI, 5.623 to 11.243) with 74.2% maturity. Median TTD was 7.633 months (95%CI, 3.688 to 11.579). The clinical response rate was 77.4%. The LM ORR and DCR assessed by investigator according to RANO-LM radiologic criteria were 54.2% and 95.8%, respectively. The safety profiles were consistent with previous reports for furmonertinib.
Conclusions
Furmonertinib 240mg/day has demonstrated clinically significant efficacy as first line and salvage therapy in patients with EGFR-mutant NSCLC and leptomeningeal metastases.
Clinical trial identification
ChiCTR2300072092.
Editorial acknowledgement
Legal entity responsible for the study
Qiming Wang.
Funding
Henan Province Health and Youth Subject Leader Training Project (No. [2020]60) The Excellent Young Talent Cultivation Project of Henan Health Science and Technology Innovation Talents (No. YXKC2020046). Henan International Joint Laboratory of drug resistance and reversal of targeted therapy for lung cancer (No. [2021]10).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract